共 50 条
- [21] Phase 1 study of AMG 386, an anti-angiogenic Fc fusion protein targeting angiopoietin-1 and-2, in Japanese patients with advanced solid tumorsCANCER RESEARCH, 2011, 71Doi, ToshihikoOhtsu, AtsushiFuse, NozomuYoshino, TakayukiTahara, MakotoSuzuki, NorikoShibayama, KazuhiroTakahara, EijiNakai, KatsuhikoWeinreich, David M.
- [22] A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal CancerCANCER IMMUNOLOGY RESEARCH, 2025, 13 (01) : 9 - 22Huffman, Brandon M.Rahma, Osama E.Tyan, KevinLi, Yvonne Y.Giobbie-Hurder, AnitaSchlechter, Benjamin L.Bockorny, BrunoManos, Michael P.Cherniack, Andrew D.Baginska, JoannaMarino-Enriquez, AdrianKao, Katrina Z.Maloney, Anna K.Ferro, AllisonKelland, SarahNg, KimmieSingh, HarshabadWelsh, Emma L.Pfaff, Kathleen L.Giannakis, MariosRodig, Scott J.Hodi, F. StephenCleary, James M.
- [23] Alliance A091103: A multicenter phase II study of the angiopoietin-1 and-2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS).JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)D'Angelo, Sandra P.Mahoney, Michelle R.Van Tine, Brian AndrewAdkins, DouglasPerdekamp, Maria T. GrosseCondy, Mercedes M.Hartley, Eliza WoodwardAntonescu, Cristina R.Schwartz, Gary K.Tap, William D.
- [24] A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and-2 Inhibitor, in Patients with Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2016, 22 (18) : 4574 - 4584Dowlati, AfshinVlahovic, GordanaNatale, Ronald B.Rasmussen, ErikSingh, IndrajeetHwang, Yuying C.Rossi, JohnBass, Michael B.Friberg, GregoryPickett, Cheryl A.
- [25] Safety, pharmacokinetics, and antitumor activity of MEDI3617, a selective angiopoietin inhibitor, in adult patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Natale, Ronald B.Rizvi, Naiyer A.Infante, Jeffrey R.Joseph, Lindsay J.Viner, JayeMcDevitt, Jennifer T.Ji, FeiShin, SoyoungLiang, MeinaBurris, Howard A.
- [26] AMG 102, an HGF/SF antagonist, in combination with anti-angiogenesis targeted therapies in adult patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Rosen, P. J.Sweeney, C. J.Park, D. J.Rasmussen, E.Shubhakar, P.Scripture, C.Leitch, I.Lu, J.Beaupre, D. M.Yee, L. K.
- [27] Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumorsINVESTIGATIONAL NEW DRUGS, 2015, 33 (01) : 159 - 168Puzanov, IgorSosman, JeffreySantoro, ArmandoSaif, Muhammad W.Goff, LauraDy, Grace K.Zucali, PaoloMeans-Powell, Julie A.Ma, Wen WeeSimonelli, MatteoMartell, RobertChai, FengLamar, MariaSavage, Ronald E.Schwartz, BrianAdjei, Alex A.
- [28] Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumorsInvestigational New Drugs, 2015, 33 : 159 - 168Igor PuzanovJeffrey SosmanArmando SantoroMuhammad W. SaifLaura GoffGrace K. DyPaolo ZucaliJulie A. Means-PowellWen Wee MaMatteo SimonelliRobert MartellFeng ChaiMaria LamarRonald E. SavageBrian SchwartzAlex A. Adjei
- [29] Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumorsExperimental Hematology & Oncology, 10Kyaw Z. TheinSarina A. Piha-PaulApostolia TsimberidouDaniel D. KarpFilip JankuSiqing FuVivek SubbiahDavid S. HongTimothy A. YapJatin ShahDenái R. MiltonLacey McQuinnJing GongYanyan TranBrett W. CarterRivka ColenFunda Meric-BernstamAung Naing
- [30] A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2010, 16 (09) : 2677 - 2687Rosen, Peter J.Sweeney, Christopher J.Park, Dorothy J.Beaupre, Darrin M.Deng, HongjieLeitch, Ian M.Shubhakar, PoornimaZhu, MinOliner, Kelly S.Anderson, AbrahamYee, Lorrin K.